Investor Update

Ad hoc announcement pursuant to Art. 53 LR

Basel, 23 October 2025

Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

- **Group sales** grew by 7%[1] at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and diagnostics.
- **Pharmaceuticals Division** sales rose by 9% (4% in CHF) due to continued high growth in sales of medicines for the treatment of severe diseases; Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (serious eye diseases) and Ocrevus (multiple sclerosis) were the top growth drivers.
- **Diagnostics Division** sales increased by 1% (-4% in CHF) as demand for pathology solutions and molecular diagnostics more than offset the impact of healthcare pricing reforms in China.
- **Highlights:**
    - US approval for **Tecentriq** combination for a form of lung cancer and **Gazyva/Gazyvaro** for a severe kidney disease
    - EU CE mark for **Contivue,** a port delivery platform with **Susvimo***, for a severe eye disease
    - Positive EU CHMP recommendation for the subcutaneous formulation of **Lunsumio** for a type of blood cancer and for **Gazyva/Gazyvaro** for a severe kidney disease
    - Positive data from phase III study on **giredestrant** in breast cancer, phase II open-label extension study on **fenebrutinib** in multiple sclerosis, phase I/II study on **trontinemab** in Alzheimer's disease and long-term follow-up studies on **Vabysmo** and **Susvimo** in a severe age-related eye disease
    - Advancement of several key drug candidates into phase III trials: **zilebesiran** for uncontrolled hypertension, **CT-388** for obesity, **CT-868** for type 1 diabetes, **cevostamab** for a difficult-to-treat form of blood cancer and **ZN-1041** for a type of breast cancer
    - Announcement of a merger agreement to acquire **89bio** and its phase III **FGF21** analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease that is one of the most prevalent comorbidities of obesity

F. Hoffmann-La Roche Ltd 4070 Basel Switzerland
Investor Relations email: investor.relations@roche.com
Phone +41 61 688 88 80 www.roche.com

- EU CE mark and US approval for the **Elecsys pTau181**, the only FDA-cleared blood test for use in primary care to rule out Alzheimer's disease-related amyloid pathology
- EU CE mark for the first **AI-based risk stratification tool** to assess progressive decline in kidney function and for the **sixth-generation Troponin T test**, which shows a new level of accuracy critical in diagnosing heart attacks

- **Outlook for 2025 earnings raised.**

Roche CEO Thomas Schinecker: "We continue to build on our positive momentum with strong sales growth of 7% at constant exchange rates.

Our momentum is further reflected in our pipeline with a number of positive clinical read-outs and a record ten potentially transformative medicines progressing into the final phase of development for diseases with significant unmet need. By the end of the decade, we expect phase III clinical results for up to 19 new medicines.

Our groundbreaking next-generation sequencing technology, set to launch next year, has achieved a new record for decoding a whole human genome in under four hours.

Based on our strong results, we are raising our earnings outlook for the full year."

Sales	CHF millions		As % of sales		% change	
January–September	2025	2024	2025	2024	At CER	In CHF
Group	45,862	44,984	100.0	100.0	7	2
Pharmaceuticals Division	35,555	34,257	77.5	76.2	9	4
United States	18,798	18,166	41.0	40.4	8	3
Europe	6,818	6,613	14.9	14.7	5	3
Japan	2,139	2,083	4.7	4.6	5	3
International**	7,800	7,395	16.9	16.5	13	5
Diagnostics Division	10,307	10,727	22.5	23.8	1	-4

**Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others

Outlook for 2025 earnings raised

Roche (SIX: RO, ROG; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER). Core earnings per share are targeted to develop in the high single to low double digit range (CER). Roche expects to further increase its dividend in Swiss francs.

Group sales

In the first nine months of 2025, Roche achieved **sales** growth of 7% (2% in CHF) to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products.

The appreciation of the Swiss franc against most currencies, notably the US dollar, had an adverse impact on sales when reported in Swiss francs compared to constant exchange rates.

Sales in the **Pharmaceuticals Division** increased by 9% (4% in CHF) to CHF 35.6 billion, with medicines for severe diseases continuing their strong growth.

The top five growth drivers – Phesgo, Xolair, Hemlibra, Vabysmo and Ocrevus – achieved total sales of CHF 15.8 billion. This represents an increase of CHF 2.4 billion at CER compared to the first nine months of 2024.

This increase more than compensated for the total decrease of CHF 0.5 billion (CER) in sales of the 'loss of exclusivity (LOE)' products – the decline in sales of Avastin (various types of cancer), Herceptin (breast and gastric cancer), MabThera/Rituxan (blood cancer, rheumatoid arthritis), Lucentis (severe eye diseases) and Esbriet (lung disease) was partially offset by an increase in sales of Actemra/RoActemra (rheumatoid arthritis).

In the **United States**, sales rose by 8% due to growth in sales of Xolair, Phesgo, Ocrevus, Hemlibra, Polivy (blood cancer) and Vabysmo. This growth more than compensated for the decline in sales of medicines with expired patents.

Sales in **Europe** grew 5% as strong demand for Ocrevus and Vabysmo and the continuing uptake of Polivy, Phesgo and Hemlibra more than compensated for the lower sales of Perjeta (breast cancer) due to ongoing conversion of patients to Phesgo and the impact of biosimilar competition on Actemra/RoActemra sales.

In **Japan**, sales increased by 5%, mainly due to the strong uptake of Phesgo, Hemlibra, Vabysmo and PiaSky (paroxysmal nocturnal haemoglobinuria). Sales growth was partially offset by the decline in sales of Perjeta due to continued conversion of patients to Phesgo and of Avastin because of biosimilar erosion.

Sales in the **International** region grew by 13%, led by Phesgo, Hemlibra, Vabysmo, Xofluza (influenza) and Kadcyla (breast cancer). In China, sales rose by 9%, driven by the uptake of Phesgo due to inclusion in the government drug reimbursement list, strong sales of Xofluza and the continued roll-out of Polivy and Vabysmo.

The **Diagnostics Division's** sales increased by 1% (-4% in CHF) to CHF 10.3 billion as growth in demand for pathology solutions and molecular diagnostics more than offset the impact of healthcare pricing reforms in China.

Sales in the **Europe, Middle East and Africa (EMEA)** region increased by 6%, driven by higher sales of clinical chemistry and immunodiagnostic products. In **North America**, sales increased by 7%, with growth across customer areas. Sales in **Asia-Pacific** decreased by 15% due to healthcare pricing reforms in China. **Latin America** sales grew by 14%.

Pharmaceuticals: key developments

Compound	Milestone
Regulatory	
Gazyva/ Gazyvaro Blood cancer	**FDA approves Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis** ● The FDA approval is based on the superiority of Gazyva/Gazyvaro over standard therapy alone, as shown by the phase II NOBILITY and phase III REGENCY data ● Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study ● Lupus nephritis affects more than 1.7 million people worldwide, predominantly women of colour and childbearing age, with up to one-third of patients progressing to end-stage kidney disease
Gazyva/ Gazyvaro Blood cancer	**CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis** ● The positive recommendation is based on phase II NOBILITY and phase III REGENCY data showing the superiority of Gazyva/Gazyvaro over standard therapy alone ● Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study ● Lupus nephritis is a debilitating condition that severely impacts a person's quality of life and affects more than 1.7 million people worldwide
Tecentriq Lung cancer	**FDA approves Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC)** ● The combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study ● This is the first and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC ● The regimen is recommended in the National Comprehensive Cancer Network Guidelines for SCLC
Lunsumio Blood cancer	**CHMP recommends EU approval of subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma** ● Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years ● Subcutaneous Lunsumio has the potential to substantially reduce treatment administration time with an injection of approximately one minute, compared with an IV infusion of two to four hours ● If approved, Lunsumio would be the first treatment available for people with follicular lymphoma after two or more lines of systemic therapy, which is both fixed-duration and subcutaneously administered
Susvimo Severe eye diseases	**Roche receives CE mark for Contivue, its port delivery platform with Susvimo, for neovascular or 'wet' age-related macular degeneration (nAMD)** ● Susvimo is under review with the EMA and once approved, will be the first continuous delivery treatment for nAMD, affecting 1.7 million in the European Union ● New seven-year data from the LADDER study show Contivue with Susvimo provides good visual outcomes with stable retinal anatomy over the longer term ● With up to two refills per year, Contivue with Susvimo provides reliable, long-term vision outcomes and is approved in the US for nAMD, diabetic macular edema (DME) and diabetic retinopathy (DR)

Elevidys Duchenne muscular dystrophy	**Regulatory update on Elevidys gene therapy for Duchenne muscular dystrophy (DMD) in the EU** ● EMA's CHMP issued an opinion not to recommend Elevidys for the treatment of ambulatory individuals with DMD ● Roche will continue its dialogue with the EMA to explore a potential path forward to make Elevidys available to individuals living with DMD in the EU ● Roche believes the benefit-risk remains positive in the ambulatory DMD population ● Elevidys is the first and only disease-modifying gene therapy for DMD
Phase III, pivotal and other key read-outs	
Tecentriq Bladder cancer	**Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment** ● Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo ● IMvigor011 is the first global phase III study to read out a pioneering ctDNA-guided approach to post-surgery treatment in muscle-invasive bladder cancer ● Data was presented as part of the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025
Giredestrant Breast cancer	**Phase III evERA data showed that giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer** ● Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in the intent-to-treat (ITT) and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care endocrine therapy plus everolimus ● The giredestrant combination was well tolerated; no new safety signals were observed including no photopsia ● If approved, giredestrant plus everolimus could be the first and only oral selective oestrogen receptor degrader combination in the post-CDK inhibitor setting
Vamikibart Severe eye disease	**Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss** ● Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients ● Vision improvements were seen in both pivotal studies, achieving statistical significance in MEERKAT and nominal significance in SANDCAT ● The MEERKAT and SANDCAT trials are ongoing and the data will be discussed with health authorities globally
Ocrevus/ Fenebrutinib Multiple sclerosis	**Roche presents new data for Ocrevus and fenebrutinib across broad patient populations at the 2025 Conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)** ● Ocrevus subcutaneous maintains a consistent benefit-risk profile after two years ● New late-breaking data confirm that Ocrevus significantly reduces disability progression in adults with advanced primary progressive multiple sclerosis (PPMS) ● One-year data reinforce that the majority of infants potentially exposed to Ocrevus during pregnancy or breastfeeding exhibit antibody responses ● Fenebrutinib two-year phase II data demonstrate near-complete suppression of disease activity at 96 weeks

Giredestrant Breast cancer	**Positive phase III results show giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer** ● evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in intent-to-treat (ITT) and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of care plus everolimus ● The all-oral combination was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments; no new safety signals were observed ● evERA is the first positive head-to-head phase III trial investigating an all-oral selective oestrogen receptor degrader-containing regimen versus a standard of care combination
Vabysmo Severe eye diseases	**New data for Vabysmo reinforce its efficacy, safety and durability in neovascular or 'wet' age-related macular degeneration (nAMD)** ● In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over four years, with nearly 80% of patients on extended dosing by study end ● Over 60% of people with a difficult-to-treat form of nAMD showed no signs of damaging lesions in the SALWEEN study, and clinically meaningful vision improvements were observed ● Vabysmo was well tolerated with a consistent long-term safety profile in nAMD in both studies
Susvimo Severe eye diseases	**Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)** ● Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 ● With two refills per year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in approximately 95% of patients ● Susvimo was well tolerated over five years and has a well-characterised safety profile
Trontinemab Alzheimer's disease	**Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceuticals portfolios at the Alzheimer's Association International Conference (AAIC)** ● Trontinemab's phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% ● Design of the phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 ● Plans for new phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline ● New real-world data support Elecsys pTau217 as a stand-alone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology
Other	
Data at ESMO	**Roche data presented at the European Society for Medical Oncology (ESMO) Congress 2025 showcase advances in science and cancer care across multiple tumour types** ● Roche presented more than 30 abstracts across more than 10 cancer types at the ESMO Congress 2025, held 17–21 October 2025 in Berlin, Germany ● The data underscore Roche's commitment to deliver transformative medicines for some of the most challenging cancer types, including breast cancers, lung cancers, gastrointestinal and genitourinary cancers

Change in Board of Directors	**Change in the Roche Board of Directors** ● Dr Claudia Suessmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at the Annual General Meeting in 2026 ● She will be nominated for election to the board of another company which is serving the healthcare industry ● Dr Claudia Suessmuth Dyckerhoff has served on the Roche Board of Directors since March 2016
89bio tender offer	**Roche commences tender offer for all shares of 89bio, Inc. for USD 14.50 per share in cash, plus a non-tradeable contingent value right for up to USD 6.00 per share in cash** ● The tender offer is being made pursuant to the previously announced merger agreement dated as of 17 September 2025, among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc., and 89bio ● The tender offer period will expire at one minute after 11:59 p.m., New York City time on 29 October 2025, unless the offer is extended
89bio merger agreement	**Roche enters into a definitive merger agreement to acquire 89bio and its phase III FGF21 analogue for the therapy of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH)** ● 89bio's pegozafermin allows for a potentially best-in-disease treatment for moderate to severe MASH, one of the most prevalent comorbidities of obesity ● The acquisition supports Roche's strategy as it enhances the company's portfolio in cardiovascular, renal and metabolic diseases and offers optionality for future combination development ● Roche will acquire 89bio for USD 14.50 per share in cash at closing, representing a total equity value of approximately USD 2.4 billion. Stockholders would also receive a non-tradeable contingent value right for up to an aggregate of USD 6.00 per share in cash, representing a total deal value of up to approximately USD 3.5 billion
Zilebesiran Hypertension	**Roche and Alnylam advance zilebesiran into a global phase III cardiovascular outcomes trial for people with uncontrolled hypertension** ● Phase III trial informed by comprehensive KARDIA data set generated through three phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 ● In the phase II KARDIA-3 study, presented as a late breaker at the European Society of Cardiology Congress 2025, zilebesiran demonstrated clinically meaningful reductions in office systolic blood pressure at month three with continuous control through month six ● Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
North Carolina manufacturing facility	**Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA** ● The USD 700 million project is part of Roche's USD 50 billion investment in US manufacturing, infrastructure and R&D ● The facility will create more than 1,900 jobs and support the production of next-generation metabolic medicines, including treatments for obesity ● These investments underscore Roche's commitment to innovative manufacturing, designed to bring life-changing treatments to patients faster

Pharmaceuticals sales

Sales	CHF millions		As % of sales		% change	
January–September	**2025**	**2024**	**2025**	**2024**	**At CER**	**In CHF**
Pharmaceuticals Division	35,555	34,257	100.0	100.0	9	4
United States	18,798	18,166	52.9	53.0	8	3
Europe	6,818	6,613	19.2	19.3	5	3
Japan	2,139	2,083	6.0	6.1	5	3
International	7,800	7,395	21.9	21.6	13	5

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others

Top 20 best-selling pharmaceuticals	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus Multiple sclerosis	5,190	7	3,613	4	1,060	12	-	-	517	24
Hemlibra Haemophilia A	3,526	12	1,941	7	740	9	275	9	570	45
Vabysmo Eye diseases (nAMD, DME, RVO)	3,063	13	2,139	4	556	24	105	26	263	115
Tecentriq Cancer immunotherapy	2,616	1	1,222	-3	650	2	262	-3	482	15
Perjeta[2] Breast cancer	2,316	-13	968	-2	418	-15	54	-39	876	-19
Xolair[2] Asthma, food allergies	2,226	34	2,226	34	-	-	-	-	-	-
Actemra/RoActemra[2] RA, COVID-19	1,893	2	926	2	450	-10	230	5	287	19

Phesgo Breast cancer	1,827	54	523	35	602	13	139	63	563	193
Kadcyla[2] Breast cancer	1,531	8	577	5	396	-6	68	-2	490	28
Evrysdi Spinal muscular atrophy	1,293	8	468	14	450	5	68	6	307	5
Alecensa Lung cancer	1,190	8	420	18	197	-8	151	8	422	7
Polivy Blood cancer	1,101	40	497	27	228	63	153	10	223	94
MabThera/Rituxan[2] Blood cancer, RA	933	-4	575	-2	104	-2	11	-11	243	-9
Activase/TNKase[2] Cardiac diseases	833	-2	797	-2	-	-	-	-	36	-13
Herceptin[2] Breast and gastric cancer	817	-19	175	-9	223	0	6	-46	413	-29
Avastin[2] Various cancer types	763	-15	225	-19	54	-14	111	-23	373	-10
Gazyva/Gazyvaro[2] Blood cancer	728	13	376	18	183	1	25	20	144	17
Pulmozyme[2] Cystic fibrosis	361	16	254	25	49	-10	-	-8	58	8
CellCept[2] Immunosuppressant	292	7	14	-11	97	22	34	28	147	-2
Madopar[2] Parkinson's disease	273	3	-	-	70	-3	-	-	203	6

DME: diabetic macular edema / nAMD: neovascular or 'wet' age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis

Diagnostics: key developments

Product	Milestone
Kidney Klinrisk Algorithm Kidney disease	**Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm and launches new comprehensive chronic kidney disease (CKD) algorithm panel** ● Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function ● This tool will be launched as part of Roche's new chronic kidney disease (CKD) algorithm panel to support care across the stages of the disease which affects 700 million people globally ● Clinicians can use the CKD panel (Kidney Klinrisk Algorithm and Kidney KFRE Algorithm) to evaluate a patient's risk of kidney function decline, including in the early asymptomatic stages of the disease
Troponin T test Heart attacks	**Data show Roche's sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks** ● Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies ● The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring patients receive the care they need at the earliest opportunity ● The global TSIX clinical study involved more than 13,000 participants, validating performance across a diverse population that reflects real-world healthcare settings
Elecsys pTau181 Alzheimer's disease	**Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease** ● Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR)-certified test to rule out Alzheimer's-associated amyloid pathology ● The minimally invasive blood-based test can serve as a rule-out for Alzheimer's pathology, reducing the need for confirmatory testing with a negative result ● Data from clinical study supports use in primary care for people with varying signs of cognitive decline

Diagnostics sales

Sales	CHF millions		As % of sales		% change	
January–September	**2025**	**2024**	**2025**	**2024**	**At CER**	**In CHF**
Diagnostics Division	10,307	10,727	100.0	100.0	1	-4
Customer areas[3]						
Core Lab	5,688	6,057	55.2	56.5	-1	-6

Molecular Lab	1,861	1,876	18.1	17.5	4	-1
Near Patient Care	1,477	1,611	14.3	15.0	-4	-8
Pathology Lab	1,281	1,183	12.4	11.0	13	8
Regions						
Europe, Middle East, Africa	3,686	3,589	35.8	33.5	6	3
North America	3,305	3,222	32.1	30.0	7	3
Asia-Pacific	2,547	3,146	24.7	29.3	-15	-19
Latin America	769	770	7.4	7.2	14	0

Third Quarter Sales 2025 Webinar

There will be a live webinar for investors and analysts today, Thursday, 23 October at 2:00 pm CEST. To access the webinar, please click here.

Additional information

Third Quarter Sales 2025 Presentation: http://www.roche.com/irp251023-a.pdf
Third Quarter Sales 2025 Presentation with appendix: http://www.roche.com/irp251023.pdf
Pharmaceuticals: key product launches in 2025: www.roche.com/pharmaq325.pdf
Diagnostics: key product launches in 2025: www.roche.com/diaq325.pdf

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

[1] Unless otherwise stated, all growth rates and comparisons to the previous year in this document are at constant exchange rates (CER: average rates 2024) and all total figures quoted are reported in CHF.
[2] Products launched before 2015.
[3] Core Lab: diagnostics solutions in the areas of immunoassays, clinical chemistry and CustomBiotech.
Molecular Lab: diagnostics solutions for pathogen detection and monitoring, donor screening, sexual health and genomics, genomic tumour profiling.
Near Patient Care: diagnostics solutions in emergency rooms, medical practices and directly with patients, including integrated personalised diabetes management.
Pathology Lab: diagnostics solutions for tissue biopsies and companion diagnostics.
In 2025, sales in the Pathology Lab customer area include sales previously reported in the Molecular Lab customer area to foster business transparency and harmonisation in the use of solutions in the area of cervical intraepithelial neoplasia technology (CINtec). The comparative information for 2024 has been restated accordingly.
In 2025, sales in the Core Lab customer area include sales previously reported in the Near Patient Care customer area to centralise digital healthcare solutions within Roche Information Solutions. The comparative information for 2024 has been restated accordingly.
* Susvimo is approved in the US by the Food and Drug Administration (FDA) for nAMD, diabetic macular edema (DME) and diabetic retinopathy (DR). It is currently under review with the European Medicines Agency (EMA) for the treatment of nAMD.

Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Roche Investor Relations

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Appendix: Tables

1. Sales January to September 2025 and 2024

CHF millions	Nine months ended 30 September		% change	
	2025	2024	At CER	In CHF
Pharmaceuticals Division	35,555	34,257	9	4
United States	18,798	18,166	8	3
Europe	6,818	6,613	5	3
Japan	2,139	2,083	5	3
International	7,800	7,395	13	5
Diagnostics Division	10,307	10,727	1	-4
Roche Group	45,862	44,984	7	2

International: Asia–Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Pharmaceuticals Div.	11,620	10	11,914	12	11,949	8	12,036	11	11,570	7
United States	6,284	9	6,608	15	6,224	6	6,446	13	6,128	5
Europe	2,188	2	2,219	10	2,320	5	2,246	5	2,252	5
Japan	717	1	791	1	671	3	754	7	714	6
International	2,431	22	2,296	11	2,734	18	2,590	11	2,476	11
Diagnostics Division	3,516	6	3,597	-1	3,491	0	3,468	0	3,348	2
Roche Group	15,136	9	15,511	9	15,440	6	15,504	8	14,918	6

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2025 vs. YTD September 2024

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	5,190	7	3,613	4	1,060	12	-	-	517	24
Hemlibra	3,526	12	1,941	7	740	9	275	9	570	45
Vabysmo	3,063	13	2,139	4	556	24	105	26	263	115
Tecentriq	2,616	1	1,222	-3	650	2	262	-3	482	15
Perjeta	2,316	-13	968	-2	418	-15	54	-39	876	-19
Xolair	2,226	34	2,226	34	-	-	-	-	-	-
Actemra/RoActemra	1,893	2	926	2	450	-10	230	5	287	19
Phesgo	1,827	54	523	35	602	13	139	63	563	193
Kadcyla	1,531	8	577	5	396	-6	68	-2	490	28
Evrysdi	1,293	8	468	14	450	5	68	6	307	5
Alecensa	1,190	8	420	18	197	-8	151	8	422	7
Polivy	1,101	40	497	27	228	63	153	10	223	94
MabThera/Rituxan	933	-4	575	-2	104	-2	11	-11	243	-9
Activase/TNKase	833	-2	797	-2	-	-	-	-	36	-13
Herceptin	817	-19	175	-9	223	0	6	-46	413	-29
Avastin	763	-15	225	-19	54	-14	111	-23	373	-10
Gazyva	728	13	376	18	183	1	25	20	144	17
Pulmozyme	361	16	254	25	49	-10	-	-8	58	8
CellCept	292	7	14	-11	97	22	34	28	147	-2
Madopar	273	3	-	-	70	-3	-	-	203	6
Enspryng	269	26	71	13	30	39	120	17	48	73
Xofluza	248	163	32	*	2	*	-	-	214	140
Elevidys	221	64	-	-	-	-	-	-	221	64

Columvi	202	81	125	97	43	66	-	-	34	51
Rozlytrek	114	22	37	3	17	10	5	-12	55	51
Lunsumio	77	47	45	15	16	25	12	-	4	*
Itovebi	68	-	61	-	1	-	-	-	6	-
Luxturna	39	178	39	178	-	-	-	-	-	-
Cotellic	35	22	16	41	8	-6	-	-	11	22
PiaSky	33	328	-	5	5	-	27	271	1	-
Susvimo	6	117	6	117	-	-	-	-	-	-
Ronapreve	-	-100	-	-	-	-100	-	-	-	-100
Pharma other	1,471	-9	430	-6	169	-14	283	-2	589	-13

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	1,697	11	1,688	7	1,778	6	1,728	10	1,684	6
Hemlibra	1,137	14	1,223	21	1,165	11	1,256	22	1,105	4
Vabysmo	1,022	59	1,048	43	1,018	18	1,049	19	996	4
Tecentriq	905	0	937	-1	870	0	863	-1	883	4
Perjeta	888	2	807	9	840	-10	773	-14	703	-14
Xolair	627	12	733	29	645	26	800	41	781	34
Actemra/RoActemra	672	7	697	4	619	-1	660	8	614	-2
Phesgo	445	55	496	72	593	52	604	57	630	51
Kadcyla	495	7	504	9	506	5	531	12	494	7
Evrysdi	408	13	385	10	420	18	449	-1	424	10
Alecensa	385	7	397	8	397	11	405	6	388	8
Polivy	304	24	304	34	358	42	372	51	371	30
MabThera/Rituxan	317	-14	356	-2	298	-16	332	1	303	3
Activase/TNKase	302	9	307	15	297	-2	253	-7	283	1
Herceptin	323	-13	318	-10	292	-20	268	-23	257	-15
Avastin	289	-19	290	-17	274	-15	248	-19	241	-11
Gazyva	225	8	240	25	249	15	241	12	238	13
Pulmozyme	104	4	126	18	123	10	116	13	122	26
CellCept	86	-5	116	23	98	4	98	1	96	18
Madopar	78	-9	90	15	92	2	101	1	80	8

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	1,229	9	1,179	0	1,247	3	1,215	8	1,151	1
Hemlibra	675	12	748	20	610	0	714	21	617	-1
Vabysmo	775	49	794	35	718	7	732	10	689	-4
Tecentriq	427	-8	438	-5	411	-8	408	-4	403	2
Perjeta	335	1	316	35	342	-3	335	4	291	-6
Xolair	627	12	733	29	645	26	800	41	781	34
Actemra/RoActemra	354	19	382	12	294	3	325	11	307	-6
Phesgo	146	34	166	64	179	38	169	40	175	29
Kadcyla	193	8	191	2	201	5	195	9	181	2
Evrysdi	146	18	159	29	160	15	149	10	159	18
Alecensa	136	16	153	23	130	21	146	19	144	15
Polivy	155	50	158	45	156	30	171	34	170	18
MabThera/Rituxan	193	-14	227	2	181	-14	206	2	188	5
Activase/TNKase	289	11	290	16	285	-2	242	-5	270	1
Herceptin	63	-22	64	-12	60	-12	61	-8	54	-6
Avastin	90	-20	94	-17	80	-21	76	-18	69	-16
Gazyva	116	16	130	34	131	27	122	14	123	14
Pulmozyme	72	3	90	23	84	22	83	22	87	30
CellCept	5	-9	6	-25	5	-5	4	-26	5	3
Madopar	-	-	-	-	-	-	-	-	-	-

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	322	11	345	21	344	11	362	14	354	12
Hemlibra	222	3	236	15	247	7	246	7	247	14
Vabysmo	167	104	168	88	197	42	181	25	178	9
Tecentriq	220	-3	214	0	220	5	214	1	216	0
Perjeta	161	-19	144	-9	144	-16	138	-15	136	-14
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	145	-26	150	-21	152	-19	156	-7	142	-1
Phesgo	189	33	195	32	199	18	202	13	201	9
Kadcyla	140	-5	136	5	135	-7	131	-5	130	-5
Evrysdi	149	13	137	3	145	6	147	3	158	7
Alecensa	72	0	67	-5	68	-6	65	-7	64	-10
Polivy	56	2	50	38	94	74	66	119	68	21
MabThera/Rituxan	32	-29	41	6	35	-10	35	-6	34	13
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	73	-16	76	-6	77	0	73	-2	73	2
Avastin	19	-9	22	13	14	-33	12	-46	28	47
Gazyva	62	-1	60	11	60	-3	61	4	62	1
Pulmozyme	16	-11	18	-2	18	-9	16	-16	15	-3
CellCept	21	-30	43	51	34	7	31	17	32	49
Madopar	23	-3	24	-1	23	-1	23	-9	24	0

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	88	4	108	22	82	3	101	12	92	11
Vabysmo	33	40	39	46	32	35	38	28	35	17
Tecentriq	95	0	103	2	81	-5	93	-2	88	-1
Perjeta	26	-48	24	-53	18	-51	19	-35	17	-27
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	79	11	84	11	71	5	81	6	78	4
Phesgo	38	-	48	*	40	115	50	59	49	41
Kadcyla	25	7	27	10	21	-3	24	0	23	-2
Evrysdi	22	2	27	9	20	0	26	9	22	7
Alecensa	48	2	54	4	49	12	51	-1	51	13
Polivy	51	-9	55	-3	44	2	55	14	54	14
MabThera/Rituxan	3	-30	5	-22	3	-17	4	-12	4	-3
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	3	-56	3	-57	2	-56	2	-46	2	-30
Avastin	47	-32	48	-28	36	-30	40	-21	35	-19
Gazyva	6	-17	8	-10	8	46	9	3	8	22
Pulmozyme	1	2	-	32	-	-26	-	-11	-	13
CellCept	9	-7	13	13	12	38	12	33	10	13
Madopar	-	-	-	-	-	-	-	-	-	-

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	146	23	164	37	187	16	151	23	179	35
Hemlibra	152	64	131	36	226	72	195	60	149	9
Vabysmo	47	180	47	63	71	101	98	130	94	111
Tecentriq	163	32	182	5	158	21	148	7	176	17
Perjeta	366	25	323	9	336	-9	281	-27	259	-21
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	94	52	81	26	102	26	98	25	87	7
Phesgo	72	87	87	129	175	142	183	230	205	213
Kadcyla	137	20	150	25	149	21	181	33	160	28
Evrysdi	91	8	62	-9	95	56	127	-15	85	4
Alecensa	129	4	123	4	150	12	143	2	129	8
Polivy	42	42	41	70	64	80	80	94	79	105
MabThera/Rituxan	89	-7	83	-11	79	-23	87	2	77	-5
Activase/TNKase	13	-16	17	5	12	-9	11	-37	13	18
Herceptin	184	-6	175	-9	153	-29	132	-34	128	-25
Avastin	133	-14	126	-16	144	-3	120	-15	109	-13
Gazyva	41	7	42	31	50	11	49	18	45	24
Pulmozyme	15	32	18	18	21	-10	17	7	20	34
CellCept	51	13	54	16	47	-4	51	-8	49	7
Madopar	55	-11	66	21	69	3	78	4	56	11

International: Asia–Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others